Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Phase 2
900
about 6.3 years
18+
24 sites in AZ, CO, FL +7
What this study is about
Researchers are testing the safety and effectiveness of lunsekimig over a long period in adults with asthma. The trial will last up to 100 weeks, with treatment lasting up to 96 weeks. Participants who have previously completed other studies on this medication are eligible.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lunsekimig
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants having any treatmentemergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Secondary: Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores, Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activities for 12 years and older (AQLQ[S] +12) domain and total scores, Change from parent study baseline in pre bronchodilator (BD) FEV1, Change from parent study baseline in prebronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Respiratory